Bangalore, June 07, 2007
Biocon Limited, today announced that it is entering into a Memorandum of Understanding with Deakin University, Victoria, Australia's fastest growing University in multi disciplinary research with greater focus in biotechnology and biosciences research.
The territories covered in the Memorandum of Understanding include
- The establishment of the Deakin Research Institute in Bangalore.
- Joint development of a mammalian cell bio-processing facility at Geelong, Victoria, Australia.
- Deakin through its Metabolic Research Unit will undertake research in the areas of metabolic diseases on behalf of Biocon.
Given the industry's need for high levels of innovation and increased productivity, Biocon frequently supplements its R and D efforts by working with academic institutions and biotechnology companies across the world. Biocon's R and D strategy encourages a symbiotic environment that draws on collective resources and knowledge. With Deakin's proven capability to research in multi-disciplinary environment the tie-up will attempt to harness this expertise in providing solutions in the area of mammalian cell bio-processing and metabolic diseases.
"The signing of this MOU will formally initiate collaboration in research and education between Biocon and Deakin University, Australia. This partnership will provide valuable access to a world of medical knowledge and scientific training, together with opportunities for exchange of scientists to facilitate projects in areas of mutual interest" said Ms Kiran Mazumdar-Shaw, CMD, Biocon Limited.
"It is a significant move for Deakin University, providing first class links with a leading international company in key areas of research interest including biotechnology, metabolic disease research and wine science. Deakin is proud of the great opportunities for development both in Victoria and in India to which this MoU will lead, including the Deakin Research Institute in India. We are pleased to work in partnership with our Indian colleagues" said Prof Sally Walker.
Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR.
About Deakin University
Deakin University, established in the 1970s, is Australia's fastest growing university in terms of research performance. The University provides a successful combination of traditional focus on excellent teaching and research with a desire to challenge conventional practices and to seek new ways of developing and delivering courses to its 32,000 plus students. Scholastic excellence, top quality research, industry partnerships and tailored courses are some of the key factors that make Deakin the fastest growing, relevant, innovative and a responsive University.